FY2026 EPS Estimates for CorMedix Decreased by HC Wainwright

CorMedix logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright cut its FY2026 EPS estimate for CorMedix to $0.38 from $0.54, below the $0.52 consensus estimate. The firm also forecast a Q4 2026 loss of $0.13 per share.
  • CorMedix reported a quarterly loss of $0.19 per share, missing the $0.12-loss consensus, while revenue of $54.52 million topped estimates of $51.76 million.
  • Analyst sentiment remains broadly positive: MarketBeat reports a “Moderate Buy” consensus and an average $15.22 price target. CEO Joseph Todisco also bought 80,000 shares at an average $4.89 each.
  • MarketBeat previews top five stocks to own in December.

CorMedix Inc (NASDAQ:CRMD - Free Report) - Research analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for CorMedix in a note issued to investors on Friday, November 13th. HC Wainwright analyst B. Folkes now expects that the company will earn $0.38 per share for the year, down from their prior estimate of $0.54. The consensus estimate for CorMedix's current full-year earnings is $0.52 per share. HC Wainwright also issued estimates for CorMedix's Q4 2026 earnings at ($0.13) EPS, FY2029 earnings at $0.73 EPS and FY2030 earnings at $0.97 EPS.

CorMedix (NASDAQ:CRMD - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). CorMedix had a net margin of 15.49% and a return on equity of 27.12%. The business had revenue of $54.52 million during the quarter, compared to the consensus estimate of $51.76 million.

CRMD has been the subject of several other research reports. Oppenheimer restated an "outperform" rating and set a $13.00 target price (down from $15.00) on shares of CorMedix in a research report on Friday. UBS Group set a $19.00 price objective on CorMedix in a research note on Tuesday, November 10th. Citigroup reissued a "market outperform" rating on shares of CorMedix in a report on Tuesday, November 10th. Wall Street Zen downgraded shares of CorMedix from a "hold" rating to a "sell" rating in a research note on Saturday. Finally, Weiss Ratings lowered shares of CorMedix from a "hold (c+)" rating to a "hold (c)" rating in a report on Tuesday, November 10th. Eight research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $15.22.

Check Out Our Latest Analysis on CRMD

CorMedix Price Performance

Shares of CorMedix stock opened at $4.82 on Tuesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.36 and a current ratio of 2.56. The firm's 50-day simple moving average is $7.11 and its 200-day simple moving average is $7.55. The firm has a market cap of $375.67 million, a P/E ratio of 6.99, a price-to-earnings-growth ratio of 0.90 and a beta of 1.48. CorMedix has a twelve month low of $4.65 and a twelve month high of $13.02.

Insider Transactions at CorMedix

In other CorMedix news, CEO Joseph Todisco bought 80,000 shares of CorMedix stock in a transaction dated Friday, November 13th. The shares were bought at an average price of $4.89 per share, with a total value of $391,200.00. Following the purchase, the chief executive officer owned 854,749 shares of the company's stock, valued at $4,179,722.61. This trade represents a 10.33% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 3.50% of the company's stock.

Hedge Funds Weigh In On CorMedix

Hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. grew its stake in shares of CorMedix by 167.9% during the third quarter. Goldman Sachs Group Inc. now owns 1,249,382 shares of the company's stock worth $9,620,000 after purchasing an additional 782,989 shares during the period. Entropy Technologies LP acquired a new position in CorMedix in the third quarter valued at about $332,000. Marshall Wace LLP lifted its stake in CorMedix by 53.4% in the third quarter. Marshall Wace LLP now owns 1,195,422 shares of the company's stock valued at $9,205,000 after buying an additional 415,887 shares during the period. Empowered Funds LLC boosted its holdings in CorMedix by 10.3% during the third quarter. Empowered Funds LLC now owns 268,323 shares of the company's stock worth $2,066,000 after buying an additional 25,091 shares during the last quarter. Finally, Bleakley Financial Group LLC bought a new position in CorMedix during the third quarter worth about $275,000. 34.18% of the stock is owned by institutional investors.

CorMedix Company Profile

(Get Free Report)

CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.

Read More

Earnings History and Estimates for CorMedix (NASDAQ:CRMD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CorMedix Right Now?

Before you consider CorMedix, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorMedix wasn't on the list.

While CorMedix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines